HoldsUp

Mark Hyman, MD · 2026-08-19 · Mark Hyman (host), David Perlmutter

Why 1 in 2 Seniors Get Alzheimer's (And How to Be the Exception)

41 research-tied claims examined: 2 contradicted 4 overstated 6 context 28 supported 1 unverified

2 Contradicted by research
0:19:22David Perlmuttercontradictedhigh

Accumulation of beta-amyloid in the brain is not the cause of Alzheimer's disease.

"That is absolutely not the cause of Alzheimer's disease. I say that in the book, provide the data, explain how the whole amyloid hypothesis was flawed." (said at 0:19:22)

The speaker's categorical assertion that beta-amyloid accumulation is 'absolutely not the cause of Alzheimer's disease' and that the amyloid hypothesis is entirely flawed contradicts extensive genetic, biochemical, and clinical trial evidence. Dominant mutations causing early-onset familial Alzheimer's disease (in APP, PSEN1, and PSEN2) and gene dosage effects in Down syndrome all directly alter amyloid-beta (Aβ) production or processing, establishing that Aβ dyshomeostasis is a key initiating causative factor in AD pathogenesis. While the original linear 'amyloid cascade hypothesis' has evolved—recognizing that Alzheimer's is multifactorial and that downstream tau neurofibrillary tangles, neuroinflammation, and synaptic loss drive cognitive decline—Aβ is well established as a critical upstream driver, and recently approved monoclonal antibodies that clear Aβ (e.g., lecanemab, donanemab) demonstrate statistically significant slowing of clinical disease progression.

  • contradicts: The amyloid hypothesis of Alzheimer's disease at 25 years. (EMBO molecular medicine 2016) · cited 6256x in the literature
    "Despite continuing debate about the amyloid β-protein (or Aβ) hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease (AD). Confirmation that presenilin is the catalytic site of γ-secretase has provided a linchpin: all dominant mutations causing early-onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin) of the reaction that generates Aβ." (abstract, results)
    pubmedfull study (doi)
  • context: Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis. (International journal of molecular sciences 2023) · cited 93x in the literature
    "Indeed, even Aducanumab and Lecanemab, the two antibodies recently approved by the FDA for AD therapy, as well as Donanemab showed limited efficacy on cognitive parameters in phase III clinical trials, despite their capability of markedly lowering Aβ brain load. Furthermore, preclinical evidence demonstrates that Aβ possesses several physiological functions, including memory formation, suggesting that AD may in part be due to a loss of function of this peptide. Finally, it is generally accepted that AD could be the result of many molecular dysfunctions" (abstract, results, passage verified)
    pubmedfull study (doi)
0:28:10David Perlmuttercontradictedhigh

Higher blood levels of phosphorylated tau 217 (p-tau217) serve as a biomarker indicating the loss of synapses in the brain.

"the higher the level of this p-tau217 blood test, that is an indication of loss of synapses. It is therefore—and what is causing loss of the synapses? Activation of the microglial cells." (said at 0:28:10)

The speaker claims that higher blood levels of p-tau217 indicate a loss of synapses in the brain. In Alzheimer's disease biomarker frameworks and extensive clinical literature, phosphorylated tau (including p-tau217) specifically reflects amyloid-beta plaque pathology and neurofibrillary tau tangle pathology (specifically tau phosphorylation/secretion in response to amyloidosis), not synaptic loss directly. Synaptic loss is measured by distinct fluid biomarkers (such as neurogranin, NPTX2, synaptotagmin, or SV2A PET imaging) or markers of neurodegeneration (such as neurofilament light chain [NfL]), whereas p-tau217 specifically indicates amyloid and tau pathology.

4 Overstated
0:05:09David Perlmutteroverstatedmoderate

Positive TSPO scans showing microglial activation are observed in Alzheimer's disease, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, major depressive disorder, PTSD, and long COVID.

"we see that the TSPO scan is positive, as you would expect, in Alzheimer's, in Parkinson's, in multiple system atrophy, progressive supranuclear palsy, major depressive disorder, post-traumatic stress, and even long COVID." (said at 0:05:09)

While translocator protein (TSPO) PET imaging reliably shows increased radiotracer uptake (reflecting glial activation/neuroinflammation) in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP), as well as in corticolimbic circuits in major depressive disorder, the claim is overstated for PTSD and long COVID. In long COVID, case-control TSPO PET studies have found that TSPO availability is not significantly elevated compared to healthy controls. In PTSD, in vivo TSPO PET imaging studies frequently report decreased TSPO binding (neuroimmune suppression) rather than increased TSPO signals.

0:12:24David Perlmutteroverstatedmoderate

Having type 2 diabetes increases the risk of developing Parkinson's disease by 85%.

"If you have type 2 diabetes, your risk of Parkinson's is increased by 85%." (said at 0:12:24)

Type 2 diabetes is associated with an increased risk of Parkinson's disease, but large meta-analyses show the relative risk increase is substantially lower than 85%. Comprehensive meta-analyses of prospective cohort studies consistently estimate an increased risk of roughly 15% to 37% (e.g., summary RR = 1.27, 95% CI 1.20–1.35 in a meta-analysis of 15 cohort studies encompassing nearly 30 million participants; RR = 1.22, 95% CI 1.08–1.37 in a 25-study meta-analysis). Claiming an 85% increase significantly overstates the effect size observed in the epidemiologic literature.

1:07:42David Perlmutteroverstatedlow

Interventional trials using lifestyle modification have proven effective in improving cognitive outcomes in individuals with established Alzheimer's disease.

"interventional trials using lifestyle modification have proven effective even in individuals with established Alzheimer's disease." (said at 1:07:42)

While a 2024 randomized controlled phase 2 trial by Ornish et al. (n=51) demonstrated improvements or stabilization in cognitive and functional measures (such as CGIC, CDR-SB, and CDR-Global) following a 20-week intensive multidomain lifestyle intervention in patients with mild cognitive impairment or early dementia due to Alzheimer's disease, stating that lifestyle modification has 'proven effective' in established Alzheimer's disease overstates the evidence. The existing evidence is preliminary, derived from a small sample over a short duration, and most large multidomain lifestyle trials (e.g., FINGER) have focused on dementia prevention in at-risk older adults rather than treatment of established Alzheimer's disease.

1:01:44Mark Hyman (host)overstatedvery low

C15 (pentadecanoic acid) strengthens cells to support healthy aging.

"active ingredient, C15, that strengthens your cells to support healthy aging. Don't take my word for it; look at the science." (said at 1:01:44)

While published in vitro and preclinical research suggests that pentadecanoic acid (C15:0) incorporates into lipid membranes, enhances membrane stability, inhibits ferroptosis, and shares cell-signaling pathways (such as AMPK activation and mTOR inhibition) with longevity-associated compounds, these findings stem primarily from cell-culture phenotyping assays, animal models, and theoretical reviews (the 'Cellular Stability Hypothesis'). Robust clinical trial evidence demonstrating that C15:0 supplementation strengthens human cells to promote healthy aging in humans is currently lacking, making the claim overstated.

6 Needs context
0:04:49David Perlmutterneeds contextmoderate

TSPO PET imaging can detect activated microglia in living humans.

"We now see that we can, research-wise anyway, image the brain in living humans using what's called a TSPO scan. This scan images when the microglia are activated to their destructive state." (said at 0:04:49)

TSPO (18 kDa translocator protein) PET imaging is widely used in living human research to visualize neuroinflammation and microglial activation in vivo. However, the claim requires two important qualifications: first, TSPO is not exclusive to microglia, as it is also expressed by reactive astrocytes and constitutively by vascular endothelial cells; second, elevated TSPO signal reflects overall cellular upregulation/density and does not specifically distinguish a purely 'destructive' phenotype from other states of microglial activation or repair.

0:32:28David Perlmutterneeds contexthigh

Being heterozygous for the APOE4 allele confers a five-fold increased risk of Alzheimer's disease, and being homozygous increases the risk 12-fold.

"if I'm heterozygous I have a five-fold increased risk. If I have two of them, homozygous, my risk for Alzheimer's may increase 12-fold." (said at 0:32:28)

Large meta-analyses establish that carrying APOE ε4 significantly increases the risk of Alzheimer's disease in a dose-dependent manner. In Caucasian populations compared to ε3/ε3 individuals, heterozygosity (ε3/ε4) is associated with an approximate 3-fold increased risk (odds ratio ~3.2, 95% CI 2.8–3.8, though reaching ~5.6 in Japanese cohorts), while homozygosity (ε4/ε4) increases risk approximately 12- to 15-fold (OR ~14.9 in Caucasians, 95% CI 10.8–20.6). The speaker's figures of 5-fold and 12-fold closely reflect this well-established gene-dose effect, with exact odds ratios varying somewhat by ancestral background, sex, and age.

0:51:55David Perlmutterneeds contextlow

A prospective study following 1,111 individuals over 12.7 years found that consuming an average of one serving of ultra-processed food per day was associated with a 13% increased risk of Alzheimer's disease.

"one study that was published in the Journal of Prevention of Alzheimer's—can you imagine, a Journal of Prevention of Alzheimer's? Be still my beating heart. And this study that came out last year followed a group of 1,111 individuals over a period of 12.7 years and basically asked these folks during this 12.7 year, during the period of time that we're going to study you, what do you eat? So they kept a food frequency diary. What did they find? They found that those individuals who consumed as an average one serving per day of ultra-processed foods experienced a 13% increased risk of Alzheimer's disease." (said at 0:51:55)

A prospective study from the Framingham Heart Study published in The Journal of Prevention of Alzheimer's Disease (follow-up mean 12.7 years) did find that each additional serving per day of ultra-processed food was associated with a 13% higher risk of Alzheimer's disease (HR = 1.13, 95% CI: 1.03–1.25). However, this finding was specific to participants who were younger than 68 years at baseline; no significant association was observed among individuals aged 68 or older at baseline.

0:52:55David Perlmutterneeds contextlow

In the same prospective study, consuming 10 or more servings of ultra-processed foods per day was associated with a 270% increased risk of Alzheimer's disease.

"they found that in those individuals who consumed 10 or more servings of ultra-processed foods a day... Their risk is increased 270%. That's of a disease for which we have no meaningful pharmaceutical treatment." (said at 0:52:55)

The claim accurately reflects findings from an analysis of the Framingham Heart Study Offspring cohort published in 2025 (PMID: 39863327), but requires two qualifications: 1) An adjusted hazard ratio of 2.71 represents a 2.7-fold risk (a 171% relative increase), which is often conflated with a 270% increase; and 2) this association was observed exclusively in the subgroup of participants aged <68 years at baseline (HR 2.71, 95% CI 1.18–6.24), with no significant association detected among those aged ≥68 years.

0:59:42David Perlmutterneeds contextlow

Paraquat is used experimentally in research laboratories to induce Parkinson's disease in non-human primates.

"Paraquat is used experimentally to create Parkinson's in primates in research laboratories" (said at 0:59:42)

Paraquat is widely used in laboratory research as a neurotoxin to model Parkinson's disease (PD) mechanisms and dopaminergic degeneration, and it has been administered to non-human primates in experimental research assessing striatal dopaminergic deficits. However, the claim requires qualification: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is the standard and predominant neurotoxin used to create full parkinsonian syndromes in non-human primates, whereas paraquat is primarily utilized in rodent and in vitro cellular models of PD.

1:02:52David Perlmutterneeds contextmoderate

Systemic inflammation causes microglia to polarize into a pro-inflammatory M1 phenotype that releases damaging cytokines, creating a feed-forward cycle that activates further microglia.

"inflammation from any source will shift the microglia to becoming their M1 destructive phenotype, we call it. That is a pro-inflammatory phenotype, meaning that once those microglia shift to being the evil twin... they are spitting out more and more of these damaging cytokines in the brain that further target other good microglia cells and shift them to being on the dark side" (said at 1:02:52)

The claim captures the traditional paradigm of neuroinflammation—where systemic inflammatory signals trigger microglial activation, cytokine release, and self-propagating neuroinflammatory cascades—but frames it using an outdated, oversimplified binary model. While preclinical and clinical studies confirm that peripheral inflammation promotes pro-inflammatory microglial responses and cytokine cascades, contemporary neuroscience (via single-cell transcriptomics and multi-omics) has discarded the strict binary 'M1 (destructive/pro-inflammatory) vs M2 (protective/anti-inflammatory)' classification. Microglia in vivo exhibit heterogeneous, multidimensional, and highly dynamic transcriptomic and functional states rather than a fixed 'M1 evil twin' switch.

  • supports: The Role of Microglia in Perioperative Neuroinflammation and Neurocognitive Disorders. (Frontiers in aging neuroscience 2021) · cited 73x in the literature
    "The aseptic trauma of peripheral surgery activates a systemic inflammatory response that results in neuro-inflammation; the microglia, the resident immunocompetent cells in the brain, are a key element of the neuroinflammatory response... However, microglia have also been implicated in producing harm possibly by changing its phenotype from its beneficial, anti-inflammatory state (termed M2) into an injurious pro-inflammatory state (termed M1); it is likely that there are intermediates states between these polar phenotypes and some consider that a gradient exists with a number of intermediates, rather than a strict dichotomy between M1 and M2." (abstract, results, passage verified)
    pubmedfull study (doi)
  • context: Microglial states revisited: from homeostasis to disease. (Nature reviews. Neuroscience 2026)
    "Advances in single-cell and single-nucleus transcriptomics, chromatin accessibility profiling, and spatial multi-omics have negated binary frameworks of 'resting versus activated' or 'M1 (pro-inflammatory) versus M2 (anti-inflammatory)' and revealed a multidimensional state space that supports brain development, homeostasis and adaptive responses to perturbation." (abstract, results, passage verified)
    pubmedfull study (doi)
28 Supported by research
0:00:00David Perlmuttersupportedmoderate

Between 40% and 50% of adults in the United States who live to age 85 will receive a diagnosis of Alzheimer's disease.

"When we recognize that 40 to 50% of adults in America who live to be age 85 will have a diagnosis of Alzheimer's disease" (said at 0:00:00)

Landmark US epidemiological studies, such as the East Boston community-based study by Evans and colleagues (JAMA 1989), found that 47.2% (95% CI: 37.0%–63.2%) of adults aged 85 years and older had clinically diagnosed probable Alzheimer's disease. While some newer population models estimate the point prevalence among adults aged 85 and older to be slightly lower (approximately 32% to 38%), the 40% to 50% estimate is well-established in the landmark literature for this age demographic in the United States.

0:00:15David Perlmuttersupportedmoderate

Among people aged 65 and older, 1 in 9 (or 11%) have dementia.

"at 65 years and older, risk is 1 in 9 or 11% of people age 65 or older have dementia." (said at 0:00:15)

The speaker's claim accurately reflects widely reported epidemiological statistics from the Alzheimer's Association (published in its annual Facts and Figures reports). Approximately 10.7% to 11% (or about 1 in 9) of Americans aged 65 and older have Alzheimer's dementia (an estimated 6.5 million individuals in 2022 out of roughly 58 million older adults).

0:02:34David Perlmuttersupportedmoderate

Microglial cells in their supportive state maintain synapses, neuronal function, and the blood-brain barrier.

"They maintain our synapses. They maintain the function of the neurons. They maintain the blood-brain barrier." (said at 0:02:34)

Published neurobiological literature supports the claim that homeostatic (supportive/resting) microglia play active physiological roles in CNS maintenance. In physiological conditions, microglia preserve neural circuit integrity by sculpting and pruning synapses, supporting neuronal survival and function, and participating in the neurovascular unit to help regulate and maintain blood-brain barrier integrity.

0:03:36David Perlmuttersupportedlow

M1-activated microglia destroy synapses, generate neuroinflammation, impair neuronal function, and increase the permeability of the blood-brain barrier.

"they can shift to being destructive, what I call in the book the "evil twin," the M1 configuration, where they are going around and destroying the synapses, creating that neuroinflammatory environment where the neurons can't work well anymore and the blood-brain barrier becomes more permeable" (said at 0:03:36)

The speaker's statement accurately summarizes the classical neuroimmunological model of M1 microglial activation. Pro-inflammatory (M1) microglia release pro-inflammatory cytokines, chemokines, and reactive oxygen species that generate a neuroinflammatory environment, promote aberrant synaptic pruning/loss, impair neuronal and synaptic function, and compromise blood-brain barrier (BBB) integrity (increasing permeability). Evidence for these specific mechanisms is largely derived from preclinical in vitro and animal disease models.

0:04:26David Perlmuttersupportedvery low

A higher-carbohydrate diet is associated with activation of microglial cells in the brain.

"why a higher-carb diet—and we'll unpack this today—is associated with activation of these microglial cells." (said at 0:04:26)

Preclinical evidence supports the association between high-carbohydrate (particularly refined carbohydrate and high-fructose) diets and microglial activation in the central nervous system. In rodent models, chronic consumption of high-carbohydrate or high-fructose diets consistently increases markers of microglial activation (such as IBA-1 and CD11b) and triggers neuroinflammatory cytokine signaling across brain regions such as the hippocampus and prefrontal cortex. Because this evidence is derived almost entirely from animal and mechanistic models rather than direct human neuroimaging or histological studies, the GRADE certainty is very low.

0:04:37David Perlmuttersupportedmoderate

Changes in gut bacteria leading to intestinal permeability cause increased systemic inflammation that activates microglial cells.

"permeability of the gut, of all things, from having changes in our gut bacteria leads to increased inflammation that will activate these microglial cells and shift them to becoming, again, the evil twin." (said at 0:04:37)

The described mechanistic cascade—where alterations in gut microbiota (dysbiosis) compromise the intestinal epithelial barrier, permitting the translocation of bacterial components like lipopolysaccharides into the bloodstream to trigger systemic inflammation and cross or signal across the blood-brain barrier to activate microglial cells—is well-documented in preclinical models and human experimental endotoxemia studies.

0:18:24David Perlmuttersupportedvery low

In the 1980s, Dr. Langston showed that patients who used a contaminated designer IV drug experienced immediate microglial activation that destroyed dopamine-producing substantia nigra neurons, causing Parkinson's symptoms that showed ongoing microglial activity 13 to 14 years later.

"It's the same mechanism that was demonstrated by Dr. Langston in the 1980s when he first saw these patients who used a designer IV drug that was contaminated. The microglia were activated in their brains immediately and destroyed those cells that made the dopamine, and immediately they got Parkinson's. And he studied their brains 13, 14 years later, and these microglia were still at it, still destroying tissue." (said at 0:18:24)

The claim accurately describes the findings of Dr. J. William Langston and colleagues. In the early 1980s, Langston identified patients who developed acute parkinsonism after injecting synthetic heroin contaminated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). In a 1999 post-mortem study of three of these patients who survived between 3 and 16 years (average roughly 13-14 years), Langston's team demonstrated ongoing nigrostriatal neurodegeneration accompanied by persistent microglial activation and clustering around substantia nigra neurons long after the initial exposure. Note that the evidence certainty is graded as very low because the human finding is based on a small post-mortem case series of three individuals.

  • supports: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1… (Annals of neurology 1999) · cited 969x in the literature
    "All 3 subjects self-administered the drug under the impression it was "synthetic heroin" and subsequently developed severe and unremitting parkinsonism... Survival times ranged from 3 to 16 years. Neuropathological examination revealed moderate to severe depletion of pigmented nerve cells in the substantia nigra in each case... In Patients 1 and 2, there was gliosis and clustering of microglia around nerve cells. Patient 3 had a similar picture and also showed large amounts of extraneuronal melanin. These findings are indicative of active, ongoing nerve cell loss, suggesting that a time-limited insult to the nigrostriatal system can set in motion a self-perpetuating process of neurodegeneration." (abstract, results and conclusions)
    pubmedfull study (doi)
  • supports: Parkinson's disease and inflammatory changes. (Neurotoxicity research 2003) · cited 76x in the literature
    "Moreover, Langston and his group described the presence of active microglia in the SNpc of three patients who had been exposed to MPTP several years before death. These results suggested that the inflammatory response may increase negative feed-back into the damaged area of the cerebral parenchyma, inducing an imbalance that could perpetuate and/or accelerate neuronal death over a period of years." (abstract, passage verified)
    pubmedfull study (doi)
0:19:44David Perlmuttersupportedhigh

A Cochrane analysis of 17 studies encompassing 20,342 individuals on beta-amyloid-lowering drugs for Alzheimer's found the clinical benefit was trivial while 20% to 25% of patients developed brain hemorrhages, brain swelling, or death.

"A Cochrane analysis was published about two months ago. This was an analysis of the 17 top studies that evaluated the effectiveness of the drugs that do indeed lower beta-amyloid in the brain. The study that involved 20,342 individuals, each study lasting about 18 months, looked at two things: risk and benefit... What they found was the benefit was zilch. That's not the word they used; the word they used was "trivial." They don't work. And the risk was really high: 20 to 25% of these people on these drugs develop brain hemorrhages, and/or brain swelling, or even death" (said at 0:19:44)

The speaker accurately describes a Cochrane systematic review and meta-analysis (PMID 41985900) evaluating amyloid-beta-targeting monoclonal antibodies for early Alzheimer's disease and mild cognitive impairment. The review included exactly 17 randomized controlled trials with 20,342 participants, most lasting 18 months. The Cochrane authors concluded that these drugs produce 'little to no difference' (standardized mean differences of 0.09 to 0.12, commonly characterized as trivial/sub-clinical) in cognitive function, dementia severity, and functional ability at 18 months, while significantly increasing the risks of amyloid-related imaging abnormalities (ARIA), which encompass brain oedema (swelling) and micro-/macro-haemorrhages (bleeding), as well as serious adverse events.

0:24:13David Perlmuttersupportedvery low

Destructive M1 microglia downregulate mitochondrial function and primarily rely on glycolysis for energy production.

"The M1 destructive microglial cell does not use mitochondria to any significant degree; it's using glycolysis. So its energy production is much less efficient, much less ATP produced." (said at 0:24:13)

Preclinical cell and animal studies support the claim that pro-inflammatory (M1) microglial polarization involves immunometabolic reprogramming characterized by reduced mitochondrial oxidative metabolism and a switch toward aerobic glycolysis as the primary mode of energy production. Because glycolysis produces substantially fewer moles of ATP per mole of glucose compared to mitochondrial oxidative phosphorylation, energy production via this pathway is less biochemically efficient.

0:17:04David Perlmuttersupportedmoderate

The blood-brain barrier naturally becomes less functional and increasingly permeable as humans age.

"through the blood-brain barrier that becomes less and less functional as we age." (said at 0:17:04)

Observational neuroimaging studies (using dynamic contrast-enhanced MRI and multi-echo arterial spin labeling) and biomarker literature in humans show that blood-brain barrier (BBB) permeability increases and barrier function progressively declines as a normal feature of aging across several brain regions, an effect that is further exacerbated in age-related cognitive decline and neurodegenerative disease.

0:38:27David Perlmuttersupportedmoderate

A 2024 study in The Lancet examining 14 modifiable risk factors showed that addressing them is associated with about a 50% reduced risk of developing dementia.

"a study appearing in The Lancet in 2024 that looked at 14 modifiable factors and indicated that attention to these 14 modifiable factors is associated with about a 50% reduced risk for developing dementia." (said at 0:38:27)

The 2024 Lancet Commission report on dementia prevention, intervention, and care (Livingston et al., 2024, PMID 39096926) updated its life-course model from 12 to 14 modifiable risk factors (adding untreated vision loss and high LDL cholesterol). The report calculated that eliminating these 14 risk factors across the life course accounts for a global population attributable fraction (PAF) of approximately 45% (with subsequent regional analyses reporting up to 59.5% in lower- and middle-income regions, PMID 40823285), matching the speaker's statement of 'about a 50%' potential reduction.

0:39:42David Perlmuttersupportedmoderate

A randomized trial led by Dr. Kirk Erickson showed that aerobic exercise for one year increased the volume of the brain's hippocampus and improved cognitive function.

"from a Dr. Kirk Erickson, who randomized a group of just over 100 individuals: one group stretched, one group aerobically exercised. After one year, he did two things—he did a cognitive assessment, and he actually did three things: he measured their BDNF (we'll talk about that in a minute), and he actually measured the size using an MRI of their memory center in the brain. And he was first to demonstrate that this intervention, this program that you put people on, was associated with an increase in size of the brain's memory center, a preservation, in fact an improvement of cognitive function, just because these people exercised." (said at 0:39:42)

The speaker accurately summarizes the randomized controlled trial led by Dr. Kirk I. Erickson published in PNAS in 2011 (n=120 older adults). The study compared 1 year of moderate-intensity aerobic exercise against a stretching control group, using MRI to measure brain volumes along with tests of spatial memory and serum BDNF levels. The aerobic exercise intervention increased anterior hippocampal volume by approximately 2% and improved spatial memory, with the volume increase associated with higher serum BDNF levels.

0:40:25David Perlmuttersupportedmoderate

A 20-week trial by Rudolph Tanzi and Dean Ornish in 51 patients with Alzheimer's disease demonstrated that comprehensive lifestyle changes stopped cognitive decline in 70% of participants, with many improving.

"Rudolph Tanzi at Harvard, along with Dean Ornish, published a study last year demonstrating an interventional trial on 51 individuals—not a huge trial—over a 20-week period of time demonstrating that when they changed people's diets, allowed them to exercise regularly or invited them to exercise regularly, reduced their stress, these are individuals with Alzheimer's disease diagnosed, that their cognitive function didn't slow in its decline; by and large, it stopped declining completely. And in fact, this is in 70% of their interventional people. In many of them, it actually improved." (said at 0:40:25)

The speaker accurately describes a randomized controlled trial published in 2024 by Dean Ornish, Rudolph Tanzi, and colleagues in Alzheimer's Research & Therapy (PMID: 38849944). The study enrolled 51 patients with mild cognitive impairment or early dementia due to Alzheimer's disease in a 20-week multidomain intensive lifestyle intervention (plant-based diet, regular exercise, stress management, and support groups). The trial found that participants in the intervention group showed stabilization or improvement across several cognitive and functional measures (such as CGIC, CDR Global, and ADAS-Cog), whereas the control group experienced progression.

0:41:45David Perlmuttersupportedhigh

Muscle tissue functions as an endocrine gland by secreting chemicals that regulate metabolism and positively influence brain health.

"when we do resistance training, we're building muscles, which is really important because muscle tissue is an endocrine gland secreting various chemicals that ultimately positively influence brain health. So the muscles make chemicals that go elsewhere in the body; therefore, it's an endocrine gland more involved in regulating metabolism." (said at 0:41:45)

Extensive exercise physiology and endocrinology literature confirms that skeletal muscle functions as an endocrine organ. In response to contraction (such as resistance or aerobic exercise), muscle tissue synthesizes and secretes diverse signaling molecules collectively called myokines (e.g., irisin, IL-6, BDNF, cathepsin B). These humoral factors enter the circulation to regulate systemic metabolism (including glucose and lipid homeostasis in the liver, pancreas, and adipose tissue) and cross or influence the blood-brain barrier to promote neuroplasticity, cognitive function, and brain health.

  • supports: Muscle-brain crosstalk mediated by exercise-induced myokines - insights from experimental … (Frontiers in physiology 2024) · cited 46x in the literature
    "Over the past couple of decades, it has become apparent that skeletal muscles might be engaged in endocrine signaling, mostly as a result of exercise or physical activity in general. The importance of this phenomenon is currently studied in terms of the impact that exercise- or physical activity -induced signaling factors have, in the interaction of the "muscle-brain crosstalk." So far, skeletal muscle-derived myokines were demonstrated to intercede in the connection between muscles and a plethora of various organs such as adipose tissue, liver, or pancreas." (abstract, passage verified)
    pubmedfull study (doi)
  • supports: Skeletal Muscle as Endocrine Organ. (Advances in experimental medicine and biology 2025) · cited 4x in the literature
    "Skeletal muscle is widely recognized as an endocrine organ capable of synthesizing and secreting various cytokines and peptides collectively known as myokines. These myokines play a crucial role in the communication between muscle and other organs, including adipose tissue, liver, pancreas, bone, and brain. Research indicates that physical activity can stimulate the production of myokines in skeletal muscle, which then impact various organ functions through autocrine, paracrine, and endocrine pathways. Myokines contribute to the health benefits associated with exercise, including improved cognitive function, regulation of lipid and glucose metabolism, and promotion of muscle and bone development." (abstract, passage verified)
    pubmedfull study (doi)
  • supports: Myokine-mediated muscle-organ interactions: Molecular mechanisms and clinical significance… (Biochemical pharmacology 2025) · cited 38x in the literature
    "Recent breakthroughs in research have established the endocrine organ properties of skeletal muscle. Through contraction-induced release of myokines, skeletal muscle employs multimodal signaling mechanisms including autocrine, paracrine, and endocrine pathways, systematically elucidating the molecular basis of exercise benefits... Mechanistic insights elucidate that myokines function as pleiotropic signaling modulators, orchestrating multifaceted regulatory programs across six interconnected biological axes, including energy substrate flux and mitochondrial biogenesis, osteogenic differentiation and extracellular matrix remodeling, neuroplasticity and Blood-brain barrier (BBB) homeostasis" (abstract, passage verified)
    pubmedfull study (doi)
0:34:45David Perlmuttersupportedmoderate

In American adults, 60% of daily caloric intake comes from ultra-processed foods.

"we live in a country where in adults 60% of calories are coming from these frankenfoods, as the term you've used in the past, these ultra-processed foods that represent a clear and present danger to your brain's destiny." (said at 0:34:45)

Nationally representative dietary data from the National Health and Nutrition Examination Survey (NHANES) consistently show that ultra-processed foods contribute approximately 54% to 58% of total daily energy intake among US adults (rising from 53.5% in 2001–2002 to 57.0%–57.9% in recent survey waves). Stating that ~60% of daily caloric intake comes from ultra-processed foods is well-supported by national dietary surveillance.

0:58:55David Perlmuttersupportedhigh

Over 70 countries globally have banned or significantly restricted the agricultural use of the herbicide paraquat.

"The good news is that 70 countries around the globe, because it is such a devastating toxic exposure, paraquat, have banned or significantly reduced the use of paraquat in agriculture." (said at 0:58:55)

A 2025 systematic review of global paraquat regulations identified that at least 74 countries do not authorise paraquat in their markets through bans, phase-outs, and market withdrawals, confirming the speaker's claim that over 70 countries have banned or significantly restricted its agricultural use due to human toxicity concerns.

0:59:30David Perlmuttersupportedmoderate

Paraquat is a mitochondrial toxin whose exposure is associated with an increased risk of Parkinson's disease.

"So we've had to turn to the use of paraquat, a mitochondrial toxin exposure to which is associated with increased risk of Parkinson's, to treat the weeds in our modern agriculture." (said at 0:59:30)

The speaker accurately states that paraquat is a mitochondrial toxin and that exposure to it is associated with an increased risk of Parkinson's disease. Systematic reviews and meta-analyses of observational studies demonstrate a statistically significant positive association between paraquat exposure and Parkinson's disease risk (e.g., OR 1.64, 95% CI: 1.27–2.13 in Tangamornsuksan et al., 2019; and a 25% increased risk in Vaccari et al., 2019). Mechanistic toxicological research confirms that paraquat exerts neurotoxicity by generating reactive oxygen species and inducing mitochondrial dysfunction in dopaminergic neurons.

1:00:15David Perlmuttersupportedvery low

Glyphosate functions as a mitochondrial toxin.

"glyphosate itself, the active ingredient in Roundup—buy it at the hardware store and, you know, spray it around your vegetables, I'm telling you not to do that—is similarly a mitochondrial toxin." (said at 1:00:15)

Preclinical and mechanistic evidence demonstrates that glyphosate and glyphosate-based herbicides induce mitochondrial dysfunction, typically alongside oxidative stress, altered mitochondrial membrane potential, and impaired cellular bioenergetics across various animal and in vitro models. A 2022 systematic review of glyphosate neurotoxicity identified mitochondrial dysfunction and oxidative stress as prominent mechanisms leading to cellular damage and death. However, certainty is graded very low because available data derive from in vitro and animal experimental models, with some tissue-specific variability regarding the potency of pure glyphosate compared to formulated commercial products containing surfactant adjuvants.

0:49:43David Perlmuttersupportedmoderate

Lipopolysaccharide (LPS) leaking from the gut challenges immune cells to produce inflammatory cytokines that cross to the brain and stimulate microglial cells to become neurodestructive.

"What do these immune cells do now that they are challenged with various chemicals like LPS—people may have heard of that, lipopolysaccharide? They increase their production of these inflammatory cytokines. If we go back to our original conversation early in this interview, we remember that cytokines, these inflammatory chemicals, make their way to the brain and stimulate our microglial cells to shift from being supportive brain defenders to being destructive." (said at 0:49:43)

The biological pathway described by the speaker is well established in neuroimmunology and gut-brain axis research. Increased intestinal permeability allows lipopolysaccharide (LPS, an endotoxin from gram-negative bacterial cell walls) into systemic circulation, where it stimulates peripheral immune cells to produce pro-inflammatory cytokines (such as TNF-α, IL-1β, and IL-6). These inflammatory signals access the central nervous system via blood-brain barrier transport or neural signaling pathways, triggering microglia to shift from a homeostatic state to a reactive, neurotoxic phenotype that can damage synapses and neurons.

0:53:56David Perlmuttersupportedlow

Short-chain fatty acids produced by gut bacteria travel to the brain and regulate gene expression.

"it's the lack of production of certain metabolites, products of these bacteria that make their way to the brain, these short-chain fatty acids that are important for gene expression regulation. What did I just say? That our gut bacteria are regulating our gene expression, our life code. I better take good care of my gut bacteria because they have a big, they have a very important job. They are determining gene expression throughout my body and, yes, even in my brain, for crying out loud." (said at 0:53:56)

The claim accurately describes a recognized mechanistic pathway within the gut-brain axis: short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate are produced by bacterial fermentation in the colon, can cross the blood-brain barrier, and act as epigenetic regulators (notably via histone deacetylase [HDAC] inhibition) to alter central nervous system gene expression. However, the evidence base is graded as low certainty because it is primarily derived from preclinical animal models, in vitro assays, and pharmacological administration of SCFAs rather than direct in vivo human interventional data.

0:57:25David Perlmuttersupportedmoderate

Trichloroethylene (TCE) is an industrial cleaner and dry-cleaning solvent that contaminates groundwater, targets mitochondria, and is associated with the development of Parkinson's disease.

"what Dr. Dorsey made very clear is that we are exposed to a variety of toxins these days in our environment that directly target mitochondria and therefore can manifest as things like Parkinson's. As you discussed in your interview of Dr. Dorsey, he's really very much fixated on this trichloroethylene, which had been used—industrial cleaner, dry cleaning fluid—makes its way into water, you know, and there are places where groundwater is still contaminated by TCE." (said at 0:57:25)

The speaker's assertions accurately reflect the established scientific literature and the specific work of Dr. Ray Dorsey and colleagues. Trichloroethylene (TCE) is an industrial solvent and dry-cleaning chemical known to contaminate groundwater and soil. Mechanistic and preclinical studies show that TCE selectively inhibits mitochondrial complex I, driving oxidative stress and dopaminergic neurodegeneration in the substantia nigra. Observational and epidemiological studies have linked occupational, military (e.g., Camp Lejeune), and environmental TCE exposure to an elevated risk of Parkinson's disease.

0:58:05David Perlmuttersupportedhigh

MPTP is a mitochondrial-targeting contaminant of illicit intravenous drugs from the 1980s that causes Parkinson's disease.

"this MPTP contaminant of this IV drug that people were using in the '80s and getting Parkinson's because MPTP targets the mitochondria." (said at 0:58:05)

In 1982-1983, Langston and colleagues identified that 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP), a contaminant produced during the illicit synthesis of the meperidine analog MPPP ('synthetic heroin'), caused severe, irreversible parkinsonism in intravenous drug users. Subsequent mechanistic research established that its metabolite (MPP+) accumulates in dopaminergic neurons and selectively inhibits mitochondrial respiratory chain complex I, leading to dopaminergic neuronal death in the substantia nigra.

0:42:55Mark Hyman (host)supportedhigh

Aging naturally causes anabolic resistance, making the body lose muscle and absorb and utilize dietary protein less efficiently.

"As we age, we naturally lose muscle and become less efficient at absorbing and utilizing protein. There's actually a term for this: anabolic resistance." (said at 0:42:55)

The speaker's statement accurately summarizes age-related sarcopenia and anabolic resistance. Anabolic resistance is the established physiological term for the reduced capacity of skeletal muscle in older adults to stimulate muscle protein synthesis in response to dietary protein/amino acid ingestion and other anabolic stimuli.

1:02:11David Perlmuttersupportedlow

Inhaled PM2.5 particulate matter from sources like wildfire smoke increases systemic pro-inflammatory cytokines that travel to the brain and shift microglia into a destructive phenotype.

"These particles, these PM2.5s, are powerfully pro-inflammatory, meaning they increase the cytokines in our bodies that make their way to the brain and will shift our brain defenders, microglia cells, to becoming brain destroyers." (said at 1:02:11)

Extensive preclinical, cellular, and review literature supports the mechanistic pathway described by the speaker. Inhalation of fine particulate matter (PM2.5) induces pulmonary and systemic inflammation characterized by elevated circulating pro-inflammatory cytokines (such as IL-1β, IL-6, and TNF-α). These systemic mediators transmit inflammatory signals across the blood-brain barrier via the lung-brain axis, triggering microglial activation and phenotypic polarization toward a pro-inflammatory, neurotoxic (e.g., M1-like) state that contributes to neurodegeneration. Certainty is rated as low because direct mechanistic tracing of systemic cytokines driving microglial phenotype shifts relies primarily on in vitro and animal models.

1:02:46David Perlmuttersupportedmoderate

PM2.5 particles can be inhaled directly through the nose into the brain and induce neuroinflammation.

"And also, the PM2.5s themselves can be inhaled and make their way through the nose into the brain directly and can induce inflammation." (said at 1:02:46)

Toxicological, animal, and human post-mortem studies demonstrate that fine particulate matter (PM2.5), particularly its ultrafine nanoparticle fraction, can bypass the systemic circulation and translocate directly from the nasal cavity into the central nervous system via the olfactory mucosal and nerve pathway. Once inside the brain, these particles activate microglia and astrocytes, triggering oxidative stress and neuroinflammation.

1:05:45Mark Hyman (host)supportedmoderate

Research by Steve Cole shows that social disconnection and loneliness activate a pattern of gene expression that drives inflammation.

"I talk about this guy Steve Cole, who's come up with this whole science of how disconnection and loneliness actually activates a whole gene expression pattern that drives inflammation." (said at 1:05:45)

Research led by Steve W. Cole and colleagues in social genomics established that chronic perceived social isolation (loneliness) and social disconnection are associated with a distinct leukocyte gene expression profile known as the Conserved Transcriptional Response to Adversity (CTRA). This pattern is characterized by increased expression of pro-inflammatory genes (mediated by NF-κB/Rel transcription factor signaling) and down-regulation of antiviral (Type I interferon) and antibody-related genes across both human observational cohorts and primate experimental models.

1:08:25David Perlmuttersupportedmoderate

An interventional trial published in the New England Journal of Medicine showed that a GLP-1 receptor agonist stabilized Parkinson's disease.

"We've seen an incredible interventional trial published in the New England Journal of Medicine where Parkinson's was stabilized. I think GLP-1s have a future in the brain health arena." (said at 1:08:25)

A phase 2, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in April 2024 (the LIXIPARK trial, n=156) evaluated the GLP-1 receptor agonist lixisenatide in patients with early Parkinson's disease. At 12 months, motor disability scores (MDS-UPDRS part III) showed essentially no progression in the lixisenatide group (change of -0.04 points) compared to worsening in the placebo group (+3.04 points, p=0.007), demonstrating stabilization of motor disability progression over the 1-year study period.

1:03:52Mark Hyman (host)supportedmoderate

Chronic traumatic encephalopathy (CTE) can continue to progress and worsen even after repetitive head trauma has ceased due to an ongoing feed-forward neuroinflammatory process.

"You can induce that shift from head trauma, for example. That's why these football players with chronic traumatic encephalopathy, encephalopathy continue to worsen once they've stopped after playing football. Look at Muhammad Ali: quit boxing, stopped the head trauma, but continues to worsen once this process has taken hold." (said at 1:03:52)

CTE is recognized as a progressive neurodegenerative disease triggered by repetitive head impacts, where primary trauma initiates secondary chronic cascades—prominently sustained neuroinflammation, oxidative stress, and tau misfolding—that drive progressive neurodegeneration even after active exposure to head trauma ceases.

1 No source found (not proven false)
0:41:30David Perlmutterunverifiedlow

A meta-analysis review of 36 interventional trials with nearly 6,000 participants found that the combination of aerobic and resistance training provides the greatest cognitive benefit, especially in individuals age 65 or older and those with existing cognitive impairment.

"a study that was a review of 36 interventional trials where they put people on these programs, and it was close to 6,000 individuals. And their conclusion was: is it aerobics, is it resistance training? Their conclusion was it is both. It's the combination that seems to work best... And what Jiang and the other researchers in that report noticed was that the best bang for the buck, in other words the best response, was in individuals who were age 65 or older—you and me—and also those individuals who already had some cognitive impairment." (said at 0:41:30)

A specific meta-analysis by Jiang et al. encompassing exactly 36 interventional trials and nearly 6,000 participants evaluating the combined effects of aerobic and resistance exercise across age groups and baseline cognitive status could not be located in the search. This does not prove the claim or publication does not exist, but no matching published record was verified.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.